Family · Pharmaceutical analytical standards
Atomoxetine
A selective noradrenaline reuptake inhibitor, approved in the United States in 2002 as the first non-stimulant medicine for attention deficit hyperactivity disorder (ADHD). This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It was originally called tomoxetine: the FDA asked for a new name because it looked too much like tamoxifen, an anticancer drug, with a risk of mix-ups at the pharmacy.
No product matches your search.
EDQM standards 4
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
